Why It Matters

Health insurance technology company Curative Inc. has terminated its federal lobbying relationship with BGR Government Affairs LLC, according to a lobbying disclosure filing submitted in Q2 2026. The LDA termination became effective May 1, 2026, with the filing signed on Monday, June 15.

The move marks a notable shift for the Austin-based firm, which has undergone significant business transformation over the past six years. What started as a diagnostic company pivoted dramatically during the pandemic before settling into its current focus on employer-sponsored health insurance.

The lobbying client termination came with minimal reported activity. Curative Inc. reported $0 in lobbying expenses for the period covered by the termination filing, and no specific lobbying issues were listed in the disclosure documents. This suggests the federal lobbying engagement had already become dormant before the formal LDA termination was filed.

The termination occurred roughly six months after Curative raised $150 million in Series B funding in December 2025, valuing the company at approximately $1.28 to $1.3 billion. The company achieved unicorn status with this funding round, reflecting investor confidence in its health insurance business model despite the decision to end its federal lobbying efforts.

Curative's current operations show no publicly confirmed active federal contracting in its health insurance business. This stands in sharp contrast to the company's earlier years, when it secured significant government work. In July 2020, the U.S. Department of Defense (DoD) awarded Curative a $42 million CARES Act-funded contract for 250,000 oral fluid swab COVID-19 test kits to be distributed to more than 100 military treatment facilities, including laboratory analysis and reporting services.

That DoD contract represented a major validation for the then-nascent company. However, Curative began winding down its COVID-19 testing and vaccination business in 2022 and had fully transitioned into employer-sponsored health insurance by 2023. With no active federal contracts in its current line of business, the need for federal advocacy appears to have diminished accordingly.

Broader Context

Curative was founded in January 2020 by CEO Fred Turner, initially as a diagnostic tools company. The firm's trajectory shifted dramatically with the onset of the COVID-19 pandemic. At its peak, Curative operated large-scale testing and vaccination operations, backed by government contracts and investor enthusiasm for pandemic response capabilities.

The company's stated mission evolved to focus on transforming health insurance by eliminating financial barriers to care and guiding members at every step of their health journey. Its health insurance plans feature no copays, no deductibles, and no out-of-pocket costs for in-network care. Curative offers both fully-insured and level-funded plan options for employers.

Curative's coverage footprint remains limited to specific regions. The company's health insurance plans are currently available to companies headquartered in 38 counties in Texas and the states of Florida and Georgia. This geographic limitation suggests the company may not have faced pressing federal advocacy needs at the national level.

The regional concentration of Curative's business model differs substantially from national health insurance providers that might engage in broader federal lobbying around health policy, Medicare and Medicaid regulations, or other national health care issues.

Curative's competitive positioning relies on AI-driven tools to help members navigate their health journeys, distinguishing it from traditional health insurance models. This technology focus may not have required the same level of federal legislative advocacy that other health insurance companies pursue. The company is private and venture-backed, not publicly traded, giving it flexibility in how it allocates resources for government relations.

The Bottom Line

The federal lobbying termination reflects Curative's business maturation and geographic constraints rather than any apparent crisis or policy setback. The company has successfully transitioned from pandemic-era testing and vaccination operations to a sustainable health insurance business, securing substantial venture funding in the process.

With no reported lobbying expenses in the period leading up to the termination and no active federal contracts in its current business lines, Curative's decision to end its engagement with BGR Government Affairs appears to be a straightforward business decision. The company appears to be operating without ongoing federal lobbying representation at this time.

The move underscores how companies that benefited from pandemic-era government contracts and advocacy have had to reassess their federal engagement strategies as those opportunities have closed. For Curative, the shift from COVID-19 response work to employer health insurance has fundamentally altered its relationship with the federal government and its need for Washington-based advocacy support.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article